17 November 2009
follicular lymphoma, cyclophosphamide, vincristine, and prednisone, rituximab, quality-adjusted survival, health-related quality of life; quality-adjusted time without disease symptoms or toxicities of treatment
To evaluate the impact of treatment on health states that affect patients' quality of life in advanced follicular lymphoma.
A quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TwiST) analysis was performed on data from a phase III clinical trial ( Marcus et al, 2008 ).
Cyclophosphamide, vincristine, and prednisone plus rituximab (R-CVP)-treated patients gained a mean of 15.17 months in TWiST, 8.33 months in Q-TwiST, and 11.30 months less in disease relapse, without increase in toxicity compared with cyclophosphamide, vincristine, and prednisone (CVP)-treated patients.